KAEL-GemVax, a leading oncology biopharmaceutical company, today announced that it had been officially notified by the independent Data Monitoring Committee that over 1000 patients have been enrolled in the TeloVac Study, making it the world's largest ever pancreatic cancer vaccine trial. This also means that the TeloVac study is on course to finish recruitment in August 2011, with results expected in late 2012.
The TeloVac Study is a prospective, Phase III, randomised clinical trial comparing standard Gemicitabine and Capecitabine therapy with concurrent and sequential chemoimmunotherapy using KAEL-GemVax's GV-1001 anti-telomerase vaccine in locally advanced and metastatic pancreatic cancer.
KAEL-GemVax's VP Michelle Kim welcomed this latest report: "We are now approaching the end of the trial and are pleased that the committee has found neither any untoward side effects nor need to change the protocol. We also congratulate the Liverpool Cancer Trials Unit for managing to recruit such a high number of patients. This we believe will give us a results database large enough to draw meaningful conclusions on GV-1001's efficacy and performance. We look forward to starting this analysis when the trial is completed."